Arbaclofen for autism spectrum disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Nov 2025: Trial started, NCT07655115
  2. 17 Jun 2026: Trial registered, NCT07655115

The trials

NCT07655115: Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th

State
Under way
Phase
Phase 3
People
103 planned
Started
20 Nov 2025
Primary completion
31 Dec 2026
Arms
arbaclofen
Results
None posted
  1. 20 Nov 2025: Trial started
  2. 17 Jun 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.